Eisai Files Petition Against DEA - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Eisai Files Petition Against DEA



Eisai has filed a petition with the US Court of Appeals for the District of Columbia asking the court to direct the Drug Enforcement Agency (DEA) to schedule the company's anti-epilepsy drug.

Fycompa (perampanel), a new chemical entity, approved by FDA in October 2012 as an adjunctive therapy for the treatment of partial onset seizures with or without secondarily generalized seizures in patients with epilepsy age 12 and older. FDA sent its scheduling recommendation for Fycompa to the DEA in January 2013, but the DEA has not yet begun the scheduling process, according to Eisai.

In its petition for a writ of mandamus, Eisai asserted that the DEA has "unreasonably" and "egregiously" delayed the scheduling of Fycompa. The petition also challenges the justification for the delay and highlights the lack of a timetable, predictability, or transparency related to the DEA's scheduling process. In addition, Eisai asserts that the DEA's delay also continues to harm Eisai by preventing it from launching Fycompa in the United States even though Eisai demonstrated to the satisfaction of FDA that the drug is safe and effective when prescribed in accordance with its labeling.

FDA requires that sponsors of drugs that FDA recommends for scheduling wait until the scheduling process is finished before commercially distributing the product.

Source: Eisai

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here